Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

BACKGROUND: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30–40% of ER+BC will relapse despite tamoxifen treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Loi, Sherene, Haibe-Kains, Benjamin, Desmedt, Christine, Wirapati, Pratyaksha, Lallemand, Françoise, Tutt, Andrew M, Gillet, Cheryl, Ellis, Paul, Ryder, Kenneth, Reid, James F, Daidone, Maria G, Pierotti, Marco A, Berns, Els MJJ, Jansen, Maurice PHM, Foekens, John A, Delorenzi, Mauro, Bontempi, Gianluca, Piccart, Martine J, Sotiriou, Christos
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423197/
https://www.ncbi.nlm.nih.gov/pubmed/18498629
http://dx.doi.org/10.1186/1471-2164-9-239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423197/
https://www.ncbi.nlm.nih.gov/pubmed/18498629
http://dx.doi.org/10.1186/1471-2164-9-239

Ejemplares similares